CA
SWTX

CastleArk Alternatives’s SpringWorks Therapeutics SWTX Stock Holding History

CastleArk Alternatives’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-89,086
Closed -$5.65M – 252
2021
Q3 		$5.65M Buy
+89,086
New +$6.86M 0.22% 114

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CastleArk Alternatives's SWTX Position: Q4 2021 in Review

CastleArk Alternatives sold out of SpringWorks Therapeutics (SWTX) in Q4 2021, closing a stake of 89,086 shares — an estimated $5.65M sold.

CastleArk Alternatives first reported a position in SWTX in Q3 2021 and held it in 1 quarter. The position peaked at $5.65M in Q3 2021. 144 funds tracked by Wall St. Rank hold SWTX as of Q4 2021.

  • CastleArk Alternatives reported no remaining SpringWorks Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 89,086 SpringWorks Therapeutics shares in Q4 2021, an estimated $5.65M.
  • CastleArk Alternatives first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's SpringWorks Therapeutics position peaked at $5.65M in Q3 2021.
  • 144 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.